Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis

Published:2021-09 Issue: Volume:155 Page:245-255
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Wenzel Mike^ORCID,Deuker Marina,Nocera Luigi^ORCID,Collà Ruvolo Claudia,Würnschimmel Christoph^ORCID,Tian Zhe,Shariat Shahrokh F.,Saad Fred,Briganti Alberto,Tilki Derya,Graefen Markus,Kluth Luis A.,Becker Andreas,Roos Frederik C.,Chun Felix K.H.,Karakiewicz Pierre I.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

2. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

3. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

4. EAU guidelines on renal cell carcinoma;Ljungberg,2020

5. Immunotherapy is changing first-line treatment of metastatic renal-cell carcinoma;Labriola;Clin Genitourin Cancer,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population;Future Oncology;2024-06-23

2. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy;International Journal of Urology;2024-01-19

3. Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry;Kidney Cancer;2023-06-12